Loeza-Suárez Jaime, García-Luna Diana Citlalli, Hernández-Mirón Janely, Ramírez-Marcial Raúl, Valero-Gaona Grissell Alejandra
Internal Medicine, Hospital Juárez de México, México City, MEX.
Internal Medicine, Hospital Juárez de México, Mexico City, MEX.
Cureus. 2025 Apr 15;17(4):e82315. doi: 10.7759/cureus.82315. eCollection 2025 Apr.
Drug-induced liver injury (DILI) is a rare condition characterized by hepatotoxic damage, identified through the elevation of liver function tests associated with a specific drug. Statins are among the medications linked to DILI, although this association is infrequent. Recently, reports and case series have described a relationship between atorvastatin-induced DILI and autoimmune hepatitis (AIH), two conditions not commonly associated. Because there are no established clinical or diagnostic criteria for this overlap, recognition is complex and relies on the clinical course, a timeline of causality, and the exclusion of alternative diagnoses. This report presents the case of a patient in the seventh decade of life who developed atorvastatin-induced DILI, meeting the diagnostic criteria for AIH. We discuss the therapeutic approach and review the relevant literature on this rare association.
药物性肝损伤(DILI)是一种以肝毒性损伤为特征的罕见病症,通过与特定药物相关的肝功能检查指标升高得以确诊。他汀类药物是与DILI相关的药物之一,尽管这种关联并不常见。最近,报告和病例系列描述了阿托伐他汀诱导的DILI与自身免疫性肝炎(AIH)之间的关系,这两种病症通常并无关联。由于对于这种重叠情况尚无既定的临床或诊断标准,识别过程较为复杂,依赖于临床病程、因果关系时间线以及排除其他诊断。本报告介绍了一位七十多岁患者的病例,该患者发生了阿托伐他汀诱导的DILI,符合AIH的诊断标准。我们讨论了治疗方法并回顾了关于这种罕见关联的相关文献。